Acorda Therapeutics Inc (ACOR)
0.5482
-0.02
(-3.82%)
USD |
NASDAQ |
Mar 24, 16:00
0.5482
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 13.34M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -68.16% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.0910 |
| Price to Book Value | 0.1425 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.784 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.86% |
News
Headline
Wire
Time (ET)
Yahoo
03/06 15:43
MT Newswires
02/15 03:29
Yahoo
02/14 16:46
MT Newswires
01/05 17:11
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/09/2021 | 16:30 EST | Earnings Call | Q3 2021 | -- | -- | -- | |
| 11/09/2021 | -- | Results | Q3 2021 | -- | -2.00 | -- | |
| 08/05/2021 | 16:30 EST | Earnings Call | Q2 2021 | -- | -- | -- | |
| 08/05/2021 | -- | Results | Q2 2021 | -- | -1.60 | -- | |
| 05/06/2021 | 16:30 EST | Earnings Call | Q1 2021 | -- | -- | -- | |
| 05/06/2021 | -- | Results | Q1 2021 | -2.46 | -2.54 | 3.15% | |
| 03/04/2021 | 16:30 EST | Earnings Call | Q4 2020 | -- | -- | -- | |
| 03/04/2021 | -- | Results | Q4 2020 | -2.50 | -1.48 | -68.92% |
*Estimated Date/Time
Earnings
Profile
Edit
| Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. |
| URL | https://www.acorda.com |
| Investor Relations URL | http://ir.acorda.com/investors/default.aspx |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 09, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 118.57M |
| Total Expenses (TTM) | 160.60M |
| Net Income (TTM) | -65.92M |
| Total Assets (Quarterly) | 395.60M |
| Total Liabilities (Quarterly) | 301.97M |
| Shareholders Equity (Quarterly) | 93.62M |
| Cash from Operations (TTM) | -20.92M |
| Cash from Investing (TTM) | -0.136M |
| Cash from Financing (TTM) | 0.00 |
Ratings
Profile
Edit
| Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. |
| URL | https://www.acorda.com |
| Investor Relations URL | http://ir.acorda.com/investors/default.aspx |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 09, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ACOR Tweets |